6505--Kura Oncology, Inc. Effective: 05-15-2026 to 05-14-2031

The contract, awarded to Kura Oncology, Inc. under solicitation number 36F79726D0123, is a Federal Supply Schedule (FSS) agreement administered by the Department of Veterans Affairs through its OPAL/National Acquisition Center in Hines, Illinois. The award, effective from May 15, 2026, through May 14, 2031, carries a total value of $7,000,000 and is classified under NAICS code 325412 for pharmaceutical preparation manufacturing. While the contract identifies the principal place of performance as San Diego, California, at the contractor’s office, all administrative functions, including payments and inquiries, are handled by the VA’s FSS Service in Hines, IL, with direct contact available through the FSS Help Desk via email or phone. The contract operates under the VA FSS framework, which typically involves indefinite-delivery/indefinite-quantity structures for commercial pharmaceutical products, though the specific line items, quantities, unit pricing, and product descriptions are not disclosed in the available data. No detailed clauses, specifications, inspection criteria, packaging requirements, or special provisions are provided in the documentation, indicating reliance on standard FSS terms and commercial item acquisition rules under the Federal Acquisition Regulation. The award does not indicate any specific socioeconomic set-asides, small business status, or affirmative certifications beyond the absence of Recovery Act funding. The Unique Entity ID for the contractor is listed as PSETF5F98MV1, but CAGE code and other representation details are unavailable. Payment processing and contract administration are coordinated centrally through the VA’s FSS office, with no named contracting officer, COR, or COTR identified. The contract appears to be a streamlined procurement resulting from the VA’s pre-negotiated FSS program, designed for efficient acquisition of pharmaceuticals without requiring full solicitations, evaluation factors, or detailed performance specifications beyond the foundational commercial product offerings under the FSS schedule.